Abhinav Bhalaik

Practice Areas

Corporate and M&A

Private Equity & Venture Capital

Career

Abhinav is a key member of the Private Equity, Mergers & Acquisitions and Securities Law practice of the Firm.

Abhinav regularly advises various private equity firms, venture and investment funds, corporate strategic investors, multinational corporations, and investment banks on a variety of complex domestic and cross-border mergers and acquisitions, growth capital and early-stage investments. He also represents portfolio companies of clients with respect to general corporate counselling, transactional matters and shareholder disputes. Abhinav’s sector focus includes healthcare and life sciences, manufacturing and industrials, financial services, consumer, and sports and gaming.

Abhinav was previously a partner at SAM & Co., Mumbai. He finished his B.A. LL.B. with honors in corporate law from the National Law University, Jodhpur, India.

Professional Memberships

Bar Council of Maharashtra & Goa.

Work Highlights

ArcelorMittal Nippon Steel on its bid to buy the Indian electrical steel business of Thyssenkrupp (approx. USD 500 million).

Infinx Healthcare on its fund raise from KKR and Norwest Venture Partners (approx. USD 150 million).

Zeno Health on its $25 million Series C funding round and acquisition of Tablt Pharmacy.

Ind Swift Laboratories Limited and its promoters on the sale of its API and CRAMS businesses (approx. USD 200 million) and the sale of the intermediates manufacturing business of Essix Biosciences Limited to India Resurgence Fund.

Jungle Ventures on its various investments in India, including in Showroom B2B, Kisaansay and a manufacturer of electronics for military systems.

Krafton Inc. on its various investments in India, including in Pratilipi and Deftouch.

Berkshire Hathaway on its potential exit from Paytm as part of the approx. USD 20 billion IPO.

Sequoia Capital on its investment in Rebel Foods, Eruditius, Capillary, NextSCM, Bukukas, Scaler and CarDekho.

Whiteboard Capital on its investment in ApnaKlub, ONWo, Atomberg and exit from Dezerv.

Malabar Investments on its investments in boat (approx. USD 15 million) and Games 24×7 (approx. USD 50 million investment).

CRED on its multiple rounds of fund raise from various investors including USD 140 million funding round led by GIC at a post money valuation of USD 6.4 billion.

MedGenome on its USD 50 million Series D fund raise, led by Novo Holdings.

RTP on its various investments, including in Mesh and Rebel Foods.

A 91 on its investment in Indiejewel Fashions, Hector Beverages and La Renon Healthcare.

Quona Capital on its investment in Arya Warehousing (approx. USD 21 million).

L&T Financial Services on its agreement to raise funds from Apis (approx. USD 100 million).

Panacea Biotech Limited on its USD 130 million fund raise from the Rise Fund.

Brookfield on its proposed acquisition of Suzlon Energy in a potential IBC scenario.

Goldman Sachs on its proposed investment in Manipal for its bid for Fortis (approx. USD 1.2 billion).

Avenue Capital on its investment in ARCIL.

Sumitomo on its joint venture with the Mahindra group relating to the agro chemical business.

Cemex on its proposed acquisition of an Indian listed company (approx. USD 1.5 billion).

OMERS on its investment in HDFC (overall transaction value approx. USD 1.1 billion).

TPG on its proposed investment in Max Financial for acquisition of IDBI Federal Life Insurance (approx. USD 800 million).

TPG on its sale of Healthium to Apax (approx. USD 300 million).

TPG and QRG on their investment in Campus Shoes.

Diageo on its acquisition of a majority stake in USL, for an approximate consideration of USD 2.2 billion.

Danone on its acquisition of Wockhardt’s nutrition business (approx. USD 300 million).

Actis on its various investments and exits in India, including its exit from National Stock Exchange of India Limited and Paras Pharmaceuticals Limited to Reckitt Benckiser for approx. USD 726 million.